Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025

Q32 Bio Inc.

Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.
Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.
Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.
OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.
All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.